Trials / Completed
CompletedNCT00967681
Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease
Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Catalysis SL · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Oncoxin | (caplets 300 mg), three oral caplets per day for 24 weeks |
| DIETARY_SUPPLEMENT | Placebo | (caplets 300 mg), three oral caplets per day for 24 weeks |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2009-08-28
- Last updated
- 2012-05-04
Locations
1 site across 1 country: Cuba
Source: ClinicalTrials.gov record NCT00967681. Inclusion in this directory is not an endorsement.